Clinical Trial Update: Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cabazitaxel in metastatic castration-resistant prostate cancer patients with AR-V7 positive circulating tumor cells has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Prostatic Neoplasms | Phase 2 | Status: WITHDRAWN